Physician profile
Sherry Ray
NPI 1548341175
$2,616.79
in general payments reported to CMS, 2019-2025
29 companies · $918 in 2025
The $918 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.23 · 2023: $750 · 2024: $887 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,554.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $545.74 | 2023-2025 | |
| Pfizer INC. | $305.43 | 2023-2025 | |
| Lilly USA, LLC | $277.56 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $270.57 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $180.43 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $132.38 | 2023-2025 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $108.58 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.93 | 2022-2025 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $70.08 | 2023-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.74 | 2023-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $58.02 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Astrazeneca Pharmaceuticals Lp | $56.88 | 2024 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $53.57 | 2023-2024 | |
| Amgen INC. | $52.90 | 2023-2025 | Repatha, Otezla, Evenity |
| Lundbeck LLC | $42.39 | 2025 | Vyepti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $39.26 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $35.43 | 2023 | |
| Inspire Medical Systems, INC. | $28.85 | 2024 | Inspire |
| Linvatec Corporation | $26.60 | 2025 | Hall Power |
| Axsome Therapeutics, INC. | $24.77 | 2025 | Symbravo |
| Corcept Therapeutics | $23.91 | 2024 | Korlym |
| Tolmar, INC. | $19.55 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.18 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $17.55 | 2025 | |
| Phathom Pharmaceuticals, INC. | $15.97 | 2024 | Voquezna |
| Medtronic, INC. | $15.58 | 2023 | Intellis Adaptivestim |
| Shield Therapeutics INC | $15.36 | 2025 | |
| Exact Sciences Corporation | $14.20 | 2025 | The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.